134 related articles for article (PubMed ID: 35946566)
1. Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities.
Kwok WC; Lam DCL; Ip MSM; Tam TCC; Ho JCM
Anticancer Drugs; 2022 Nov; 33(10):1139-1144. PubMed ID: 35946566
[TBL] [Abstract][Full Text] [Related]
2. Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
Suzumura T; Kimura T; Kudoh S; Umekawa K; Nagata M; Matsuura K; Tanaka H; Mitsuoka S; Yoshimura N; Kira Y; Nakai T; Hirata K
BMC Cancer; 2012 Dec; 12():568. PubMed ID: 23207012
[TBL] [Abstract][Full Text] [Related]
3. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
Han SY; Zhao HY; Zhou N; Zhou F; Li PP
J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
[TBL] [Abstract][Full Text] [Related]
4. Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers.
Chen YR; Yu X; Xu LM; Mei J; Tian ML; Xu M; Jin QY; Ye LB; Yang SX
Xenobiotica; 2024 Jan; 54(1):38-44. PubMed ID: 38085693
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.
Takimoto T; Kijima T; Otani Y; Nonen S; Namba Y; Mori M; Yokota S; Minami S; Komuta K; Uchida J; Imamura F; Furukawa M; Tsuruta N; Fujio Y; Azuma J; Tachibana I; Kumanogoh A
Clin Lung Cancer; 2013 Sep; 14(5):502-7. PubMed ID: 23664723
[TBL] [Abstract][Full Text] [Related]
6. Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.
Sugiyama E; Umemura S; Nomura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Tsuboi M; Ohe Y; Goto K
Lung Cancer; 2015 Nov; 90(2):307-13. PubMed ID: 26323212
[TBL] [Abstract][Full Text] [Related]
7. Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib.
Kobayashi H; Sato K; Niioka T; Takeda M; Okuda Y; Asano M; Ito H; Miura M
Med Oncol; 2016 Jun; 33(6):57. PubMed ID: 27154635
[TBL] [Abstract][Full Text] [Related]
8. Effects of p450 Polymorphisms on the Clinical Outcomes of Gefitinib Treatment in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer.
Fan R; Zhao J; Wang B; Li X; Guan Y; Ren P; Sun R; Zhang L; Guo Y
Genet Test Mol Biomarkers; 2022 Dec; 26(12):582-588. PubMed ID: 36577124
[No Abstract] [Full Text] [Related]
9. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
11. Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer.
Kobayashi H; Sato K; Niioka T; Miura H; Ito H; Miura M
Clin Lung Cancer; 2015 Jul; 16(4):274-81. PubMed ID: 25554506
[TBL] [Abstract][Full Text] [Related]
12. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
Giovannetti E; Zucali PA; Peters GJ; Cortesi F; D'Incecco A; Smit EF; Falcone A; Burgers JA; Santoro A; Danesi R; Giaccone G; Tibaldi C
Mol Cancer Ther; 2010 Mar; 9(3):581-93. PubMed ID: 20159991
[TBL] [Abstract][Full Text] [Related]
13. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Swaisland HC; Cantarini MV; Fuhr R; Holt A
Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer.
Zenke Y; Umemura S; Sugiyama E; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Goto K
Lung Cancer; 2016 Sep; 99():1-3. PubMed ID: 27565905
[TBL] [Abstract][Full Text] [Related]
15. Specific CYP450 Genotypes in the Chinese Population Affect Sorafenib Toxicity in HBV/HCV-associated Hepatocellular Carcinoma Patients.
Guo XG; Wang ZH; Dong W; He XD; Liu FC; Liu H
Biomed Environ Sci; 2018 Aug; 31(8):586-595. PubMed ID: 30231963
[TBL] [Abstract][Full Text] [Related]
16. Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.
Ma Y; Xin S; Huang M; Yang Y; Zhu C; Zhao H; Zhang Y; Chen L; Zhao Y; Li J; Zhuang W; Zhu X; Zhang L; Wang X
Pharmacogenomics J; 2017 Jul; 17(4):325-330. PubMed ID: 27089937
[TBL] [Abstract][Full Text] [Related]
17. Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
Hirose T; Fujita K; Kusumoto S; Oki Y; Murata Y; Sugiyama T; Ishida H; Shirai T; Nakashima M; Yamaoka T; Okuda K; Ohmori T; Sasaki Y
Lung Cancer; 2016 Mar; 93():69-76. PubMed ID: 26898617
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers.
Chhun S; Verstuyft C; Rizzo-Padoin N; Simoneau G; Becquemont L; Peretti I; Swaisland A; Wortelboer R; Bergmann JF; Mouly S
Br J Clin Pharmacol; 2009 Aug; 68(2):226-37. PubMed ID: 19694743
[TBL] [Abstract][Full Text] [Related]
19. Cranberry Ingestion Modulated Drug Transporters and Metabolizing Enzymes: Gefitinib Used as a Probe Substrate in Rats.
Yu CP; Tsai PL; Li PY; Hsu PW; Lin SP; Lee Chao PD; Hou YC
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144507
[TBL] [Abstract][Full Text] [Related]
20. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
